Olopatadine 0.1% Rescue Treatment

DRUG2 trials

Sponsors

ALK-Abelló A/S

Conditions

AllergyConjunctivitisRhinitisRhinoconjunctivitis

Phase 3

Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)

CompletedNCT00550550

ALK-Abelló A/SAllergy, Conjunctivitis, Rhinitis +1

Start: 2007-11-30End: 2009-09-30Updated: 2017-03-03

Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)

CompletedNCT00562159

ALK-Abelló A/SAllergy, Conjunctivitis, Rhinitis +1

Start: 2007-11-30End: 2009-09-30Updated: 2017-03-03

Related Papers

The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children.

2014-10-304 citations